JP2002542203A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002542203A5 JP2002542203A5 JP2000611936A JP2000611936A JP2002542203A5 JP 2002542203 A5 JP2002542203 A5 JP 2002542203A5 JP 2000611936 A JP2000611936 A JP 2000611936A JP 2000611936 A JP2000611936 A JP 2000611936A JP 2002542203 A5 JP2002542203 A5 JP 2002542203A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine composition
- tumor
- antigen
- composition according
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 22
- 229960005486 vaccines Drugs 0.000 description 18
- 239000000427 antigen Substances 0.000 description 14
- 102000038129 antigens Human genes 0.000 description 14
- 108091007172 antigens Proteins 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 8
- 229920000272 Oligonucleotide Polymers 0.000 description 6
- 230000003308 immunostimulating Effects 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 102100008453 FOLH1 Human genes 0.000 description 2
- 101700036477 FOLH1 Proteins 0.000 description 2
- 102100017963 PSCA Human genes 0.000 description 2
- 101700038464 PSCA Proteins 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-4-[(2R,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229940035032 monophosphoryl lipid A Drugs 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K Aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 206010002368 Anger Diseases 0.000 description 1
- 102100011431 BAGE Human genes 0.000 description 1
- 108060000856 BAGE Proteins 0.000 description 1
- 102100007326 BIRC5 Human genes 0.000 description 1
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 1
- 102100011842 CEACAM5 Human genes 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 102100010133 DDX43 Human genes 0.000 description 1
- 101700054602 DDX43 Proteins 0.000 description 1
- 102000003425 EC 1.14.18.1 Human genes 0.000 description 1
- 108060008724 EC 1.14.18.1 Proteins 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 102100011339 KLK3 Human genes 0.000 description 1
- 102100011337 KLK4 Human genes 0.000 description 1
- 102100006037 MUC1 Human genes 0.000 description 1
- 101700052761 MUC1 Proteins 0.000 description 1
- 102100006759 PRAME Human genes 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- ZHCXFLVDHRUYCX-UHFFFAOYSA-J aluminum;hydroxide;phosphate Chemical compound [OH-].[Al].[O-]P([O-])([O-])=O ZHCXFLVDHRUYCX-UHFFFAOYSA-J 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 230000002949 hemolytic Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 108010024383 kallikrein 4 Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Description
【特許請求の範囲】
【請求項1】 サポニン、及び免疫刺激性オリゴヌクレオチドであってC P Gもチーフを含むもの、並びに腫瘍関連抗原、腫瘍拒絶抗原、又は腫瘍支持メカニズムに関連する抗原を含むワクチン組成物。
【請求項2】 前記免疫刺激性オリゴヌクレオチドが、プリン、プリン、C,G、ピリミジン、ピリミジンの配列を含む、請求項1に記載のワクチン組成物。
【請求項3】 前記免疫刺激性オリゴヌクレオチドが、TCC ATG ACG TTC CTG ACG TT(配列番号1);TCT CCC AGC GTG CGC CAT(配列番号2);ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG(配列番号3);TCG TCG TTT TGT CGT TTT GTC GTT(配列番号4);TCC ATG ACG TTC CTG ATG CT(配列番号5)から成る群から選ばれる、請求項1に記載のワクチン組成物。
【請求項4】 前記免疫刺激性オリゴヌクレオチドが、少なくとも3つのヌクレオチドにより分離された少なくとも2つのメチル化されていないCGリピートを含む、請求項1に記載のワクチン組成物。
【請求項5】 前記免疫刺激性オリゴヌクレオチドが、少なくとも2つのメチル化されていないCGリピートであって6ヌクレオチドにより分離されているものを含む、請求項4に記載のワクチン組成物。
【請求項6】 前記サポニンがQuil Aから誘導される、請求項1〜5のいずれか1項に記載のワクチン組成物。
【請求項7】 前記Quil A誘導体がQS21である、請求項6に記載のワクチン組成物。
【請求項8】 鉱物塩、エマルジョン、ポリマー、リポソーム、ISCOMsから成る群から選ばれる粒子状担体をさらに含む、請求項1に記載のワクチン組成物。
【請求項9】 前記粒子状担体が、油/水エマルジョンである、請求項8に記載のワクチン組成物。
【請求項10】 前記粒子状担体がリポソームである、請求項8に記載のワクチン組成物。
【請求項11】 前記リポソームがコレステロールを含む、請求項10に記載のワクチン組成物。
【請求項12】 金属塩粒子を含む、請求項8に記載のワクチン組成物。
【請求項13】 前記金属塩粒子が、水酸化アルミニウム又はリン酸アルミニウムである、請求項12に記載のワクチン組成物。
【請求項14】 モノホスホリル・リピドA又は3−脱−O−アシル化モノホスホリル・リピドAをさらに含む、請求項1〜13のいずれか1項に記載のワクチン組成物。
【請求項15】 前記腫瘍関連抗原、腫瘍拒絶抗原、又は腫瘍支持メカニズムに関連する抗原が、以下の群:MAGE抗原、PRAME、BAGE、GAGE、腫瘍特異的ガングリオシド、前立腺特異的抗原、Her−2/New、KSA(GA733)、PAP、マンマグロビン(mammaglobin)、MUC−1、癌胎児抗原、前立腺特異的膜抗原(PSMA)、前立腺幹細胞抗原(PSCA)、チロシナーゼ、スルビビン(survivin)、NY−ES01、プロスターゼ(prostase)、PS108、RAGE、LAGE、HAGE、自己ペプチドホルモン又はGnRHから選ばれる1以上の抗原を含む、請求項1〜14のいずれか1項に記載のワクチン組成物。
【請求項16】 前記ワクチンが全身的に投与される、請求項1〜15のいずれか1項に記載のワクチン組成物。
【請求項17】 前記ワクチンが粘膜に投与される、請求項1〜16のいずれか1項に記載のワクチン組成物。
【請求項18】 前記ワクチン組成物のサポニンが溶血性である、請求項17に記載のワクチン組成物。
【請求項19】 医薬として使用されるための請求項1〜18のいずれか1項に記載のワクチン組成物。
【請求項20】 癌の予防又は治療用の医薬の製造における、サポニンと、免疫刺激性オリゴヌクレオチドと、腫瘍関連抗原、腫瘍拒絶抗原、又は腫瘍支持メカニズムに関連する抗原との組み合せ使用。
【請求項21】 サポニンと、免疫刺激性オリゴヌクレオチドと、腫瘍関連抗原、腫瘍拒絶抗原、又は腫瘍支持メカニズムに関連する抗原とを混合することを含む、請求項1〜19のいずれか1項に記載のワクチン組成物の製造方法。
【請求項1】 サポニン、及び免疫刺激性オリゴヌクレオチドであってC P Gもチーフを含むもの、並びに腫瘍関連抗原、腫瘍拒絶抗原、又は腫瘍支持メカニズムに関連する抗原を含むワクチン組成物。
【請求項2】 前記免疫刺激性オリゴヌクレオチドが、プリン、プリン、C,G、ピリミジン、ピリミジンの配列を含む、請求項1に記載のワクチン組成物。
【請求項3】 前記免疫刺激性オリゴヌクレオチドが、TCC ATG ACG TTC CTG ACG TT(配列番号1);TCT CCC AGC GTG CGC CAT(配列番号2);ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG(配列番号3);TCG TCG TTT TGT CGT TTT GTC GTT(配列番号4);TCC ATG ACG TTC CTG ATG CT(配列番号5)から成る群から選ばれる、請求項1に記載のワクチン組成物。
【請求項4】 前記免疫刺激性オリゴヌクレオチドが、少なくとも3つのヌクレオチドにより分離された少なくとも2つのメチル化されていないCGリピートを含む、請求項1に記載のワクチン組成物。
【請求項5】 前記免疫刺激性オリゴヌクレオチドが、少なくとも2つのメチル化されていないCGリピートであって6ヌクレオチドにより分離されているものを含む、請求項4に記載のワクチン組成物。
【請求項6】 前記サポニンがQuil Aから誘導される、請求項1〜5のいずれか1項に記載のワクチン組成物。
【請求項7】 前記Quil A誘導体がQS21である、請求項6に記載のワクチン組成物。
【請求項8】 鉱物塩、エマルジョン、ポリマー、リポソーム、ISCOMsから成る群から選ばれる粒子状担体をさらに含む、請求項1に記載のワクチン組成物。
【請求項9】 前記粒子状担体が、油/水エマルジョンである、請求項8に記載のワクチン組成物。
【請求項10】 前記粒子状担体がリポソームである、請求項8に記載のワクチン組成物。
【請求項11】 前記リポソームがコレステロールを含む、請求項10に記載のワクチン組成物。
【請求項12】 金属塩粒子を含む、請求項8に記載のワクチン組成物。
【請求項13】 前記金属塩粒子が、水酸化アルミニウム又はリン酸アルミニウムである、請求項12に記載のワクチン組成物。
【請求項14】 モノホスホリル・リピドA又は3−脱−O−アシル化モノホスホリル・リピドAをさらに含む、請求項1〜13のいずれか1項に記載のワクチン組成物。
【請求項15】 前記腫瘍関連抗原、腫瘍拒絶抗原、又は腫瘍支持メカニズムに関連する抗原が、以下の群:MAGE抗原、PRAME、BAGE、GAGE、腫瘍特異的ガングリオシド、前立腺特異的抗原、Her−2/New、KSA(GA733)、PAP、マンマグロビン(mammaglobin)、MUC−1、癌胎児抗原、前立腺特異的膜抗原(PSMA)、前立腺幹細胞抗原(PSCA)、チロシナーゼ、スルビビン(survivin)、NY−ES01、プロスターゼ(prostase)、PS108、RAGE、LAGE、HAGE、自己ペプチドホルモン又はGnRHから選ばれる1以上の抗原を含む、請求項1〜14のいずれか1項に記載のワクチン組成物。
【請求項16】 前記ワクチンが全身的に投与される、請求項1〜15のいずれか1項に記載のワクチン組成物。
【請求項17】 前記ワクチンが粘膜に投与される、請求項1〜16のいずれか1項に記載のワクチン組成物。
【請求項18】 前記ワクチン組成物のサポニンが溶血性である、請求項17に記載のワクチン組成物。
【請求項19】 医薬として使用されるための請求項1〜18のいずれか1項に記載のワクチン組成物。
【請求項20】 癌の予防又は治療用の医薬の製造における、サポニンと、免疫刺激性オリゴヌクレオチドと、腫瘍関連抗原、腫瘍拒絶抗原、又は腫瘍支持メカニズムに関連する抗原との組み合せ使用。
【請求項21】 サポニンと、免疫刺激性オリゴヌクレオチドと、腫瘍関連抗原、腫瘍拒絶抗原、又は腫瘍支持メカニズムに関連する抗原とを混合することを含む、請求項1〜19のいずれか1項に記載のワクチン組成物の製造方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9908885.8A GB9908885D0 (en) | 1999-04-19 | 1999-04-19 | Vccine |
US09/301,829 US6558670B1 (en) | 1999-04-19 | 1999-04-29 | Vaccine adjuvants |
US09/301,829 | 1999-04-29 | ||
US9908885.8 | 1999-04-29 | ||
PCT/EP2000/002920 WO2000062800A2 (en) | 1999-04-19 | 2000-04-04 | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007098596A Division JP4897547B2 (ja) | 1999-04-19 | 2007-04-04 | ワクチン |
JP2007291459A Division JP4805242B2 (ja) | 1999-04-19 | 2007-11-09 | ワクチン |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002542203A JP2002542203A (ja) | 2002-12-10 |
JP2002542203A5 true JP2002542203A5 (ja) | 2007-05-31 |
Family
ID=26315432
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000611936A Pending JP2002542203A (ja) | 1999-04-19 | 2000-04-04 | ワクチン |
JP2007098596A Expired - Lifetime JP4897547B2 (ja) | 1999-04-19 | 2007-04-04 | ワクチン |
JP2007291459A Expired - Lifetime JP4805242B2 (ja) | 1999-04-19 | 2007-11-09 | ワクチン |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007098596A Expired - Lifetime JP4897547B2 (ja) | 1999-04-19 | 2007-04-04 | ワクチン |
JP2007291459A Expired - Lifetime JP4805242B2 (ja) | 1999-04-19 | 2007-11-09 | ワクチン |
Country Status (22)
Country | Link |
---|---|
US (4) | US6544518B1 (ja) |
EP (2) | EP1187629B1 (ja) |
JP (3) | JP2002542203A (ja) |
KR (1) | KR100922031B1 (ja) |
CN (1) | CN1227030C (ja) |
AT (1) | ATE276758T1 (ja) |
AU (1) | AU764969B2 (ja) |
BR (1) | BRPI0010612B8 (ja) |
CA (1) | CA2370697C (ja) |
CZ (1) | CZ303515B6 (ja) |
DE (1) | DE60014076T2 (ja) |
DK (1) | DK1187629T3 (ja) |
ES (1) | ES2228497T3 (ja) |
HK (1) | HK1044484B (ja) |
HU (1) | HU229255B1 (ja) |
IL (1) | IL145982A0 (ja) |
NO (1) | NO331688B1 (ja) |
PL (1) | PL203951B1 (ja) |
PT (1) | PT1187629E (ja) |
TR (1) | TR200103018T2 (ja) |
TW (1) | TWI232753B (ja) |
WO (1) | WO2000062800A2 (ja) |
Families Citing this family (279)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849719A (en) * | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
GB2324093A (en) | 1996-01-04 | 1998-10-14 | Rican Limited | Helicobacter pylori bacterioferritin |
US20030078223A1 (en) * | 1996-01-30 | 2003-04-24 | Eyal Raz | Compositions and methods for modulating an immune response |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
SI1077722T1 (sl) * | 1998-05-22 | 2007-02-28 | Ottawa Health Research Inst | Metode in produkti za induciranje sluznicne imunosti |
US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US7049302B1 (en) | 1998-08-10 | 2006-05-23 | Antigenics Inc. | Compositions of CPG and saponin adjuvants and uses thereof |
NZ513935A (en) | 1999-02-17 | 2004-02-27 | Csl Ltd | Immunogenic complexes and methods relating thereto |
EP1154790B1 (en) * | 1999-02-26 | 2004-10-20 | Chiron S.r.l. | Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs |
KR100922031B1 (ko) * | 1999-04-19 | 2009-10-19 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
US20050002958A1 (en) * | 1999-06-29 | 2005-01-06 | Smithkline Beecham Biologicals Sa | Vaccines |
GB9915204D0 (en) * | 1999-06-29 | 1999-09-01 | Smithkline Beecham Biolog | Vaccine |
ATE306938T1 (de) * | 1999-06-29 | 2005-11-15 | Glaxosmithkline Biolog Sa | Verwendung von cpg als adjuvans für hivimpstoff |
UA77152C2 (en) * | 1999-09-25 | 2006-11-15 | Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma | |
US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
WO2001051083A2 (en) * | 2000-01-13 | 2001-07-19 | Antigenics Inc. | Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
CA2396871A1 (en) * | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
KR100879810B1 (ko) * | 2000-02-21 | 2009-01-22 | 하. 룬드벡 아크티에셀스카브 | 아밀로이드의 하향-조절을 위한 신규한 방법 |
JP5025871B2 (ja) * | 2000-02-21 | 2012-09-12 | エイチ.リュンドベック エイ/エス | アミロイドの新規なダウン−レギュレート方法 |
US7129222B2 (en) * | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
ES2362715T3 (es) * | 2000-03-30 | 2011-07-12 | Dendreon Corporation | Composiciones y métodos para inmunoterapia a base de células dendríticas. |
CA2420499A1 (en) * | 2000-08-25 | 2002-02-28 | Yeda Research And Development Co. Ltd. | Methods of treatment or prevention of autoimmune diseases with cpg-containing polynucleotide |
HU229642B1 (en) * | 2000-10-18 | 2014-03-28 | Glaxosmithkline Beecham Biolog S A | Vaccines against cancers |
KR100831139B1 (ko) * | 2000-10-18 | 2008-05-20 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
GB0025577D0 (en) * | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
EP2189473A3 (en) | 2000-10-27 | 2010-08-11 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic and proteins from streptococcus groups A & B |
WO2002046477A2 (en) | 2000-12-07 | 2002-06-13 | Chiron Corporation | Endogenous retroviruses up-regulated in prostate cancer |
AU2002248185A1 (en) * | 2000-12-14 | 2002-07-16 | Coley Pharmaceutical Group, Inc. | Inhibition of angiogenesis by nucleic acids |
US20040081655A1 (en) * | 2001-01-05 | 2004-04-29 | Karen Lingnau | Methods and compositions comprising polycationic compounds |
WO2002053184A2 (en) * | 2001-01-05 | 2002-07-11 | Intercell Ag | Uses for polycationic compounds as vaccine adjuvants |
US7244438B2 (en) | 2001-01-05 | 2007-07-17 | Intercell Ag | Uses for polycationic compounds |
EP1347776A2 (en) * | 2001-01-05 | 2003-10-01 | Intercell Biomedizinische Forschungs- und Entwicklungs AG | Anti-inflammatory use of polycationic compounds |
CA2434546C (en) * | 2001-01-12 | 2012-09-11 | Chiron Corporation | Induction of immune response by a replication-defective venezuelan equine encephalitis-sindbis chimeric virus replicon particle encoding an antigen |
US7713942B2 (en) | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
US20100221284A1 (en) * | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
TWI228420B (en) * | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
US8481043B2 (en) | 2001-06-22 | 2013-07-09 | Cpex Pharmaceuticals, Inc. | Nasal immunization |
EP1572124A4 (en) | 2001-06-29 | 2007-11-28 | Novartis Vaccines & Diagnostic | HCV E1E2 VACCINE COMPOSITIONS |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
US20030138434A1 (en) * | 2001-08-13 | 2003-07-24 | Campbell Robert L. | Agents for enhancing the immune response |
MY144532A (en) * | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
DE60234375D1 (de) | 2001-09-14 | 2009-12-24 | Cytos Biotechnology Ag | VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG |
CA2492823A1 (en) * | 2001-09-14 | 2003-03-27 | Martin F. Bachmann | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
GB0123580D0 (en) * | 2001-10-01 | 2001-11-21 | Glaxosmithkline Biolog Sa | Vaccine |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
US20050238660A1 (en) * | 2001-10-06 | 2005-10-27 | Babiuk Lorne A | Cpg formulations and related methods |
AU2006200116B2 (en) * | 2001-11-27 | 2009-03-19 | Schering Corporation | Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist |
TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
EP1467755A1 (en) | 2001-12-21 | 2004-10-20 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
EP1531796B1 (en) | 2002-02-20 | 2016-09-28 | GlaxoSmithKline Biologicals SA | Microparticles with adsorbed polypeptide-containing molecules |
CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
EP1532161B1 (en) | 2002-06-13 | 2012-02-15 | Novartis Vaccines and Diagnostics, Inc. | Vectors for expression of hml-2 polypeptides |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
CA2494911A1 (en) | 2002-08-12 | 2004-02-19 | Dynavax Technologies Corporation | Immunomodulatory compositions, methods of making, and methods of use thereof |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
DE60332477D1 (de) | 2002-11-15 | 2010-06-17 | Novartis Vaccines & Diagnostic | Unerwartete oberflächenproteine in neisseria meningitidis |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
AU2003300831A1 (en) * | 2002-12-11 | 2004-06-30 | Hawaii Biotech, Inc. | Recombinant vaccine against flavivirus infection |
CA2502015A1 (en) | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5' cpg nucleic acids and methods of use |
CA2511512C (en) | 2002-12-27 | 2013-10-29 | Chiron Corporation | Immunogenic compositions containing phospholipid |
WO2004084938A1 (en) * | 2003-03-24 | 2004-10-07 | Intercell Ag | Improved vaccines |
RU2351362C2 (ru) | 2003-03-26 | 2009-04-10 | Цитос Байотекнолоджи Аг | КОНЪЮГАТЫ ПЕПТИДА Melan-A, АНАЛОГА ВИРУСОПОДОБНОЙ ЧАСТИЦЫ |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
EP2258365B1 (en) | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
US20040235770A1 (en) * | 2003-04-02 | 2004-11-25 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
NZ543467A (en) | 2003-04-10 | 2008-07-31 | Novartis Vaccines & Diagnostic | The severe acute respiratory syndrome coronavirus |
PT1631264E (pt) | 2003-06-02 | 2009-11-03 | Novartis Vaccines & Diagnostic | Composições imunogénicas à base de micropartículas biodegradáveis que compreendem um toxóide de difteria e do tétano |
US20060035242A1 (en) | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
EP1670507A4 (en) * | 2003-09-12 | 2007-10-17 | Antigenics Inc | VACCINE FOR THE TREATMENT AND PREVENTION OF INFECTION CAUSED BY HERPES SIMPLEX VIRUS |
GB0323965D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
GB0323968D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
WO2005063286A1 (en) | 2003-12-23 | 2005-07-14 | Arbor Vita Corporation | Antibodies for oncogenic strains of hpv and methods of their use |
EP1550458A1 (en) * | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Synergistic liposomal adjuvants |
TWI235440B (en) * | 2004-03-31 | 2005-07-01 | Advanced Semiconductor Eng | Method for making leadless semiconductor package |
KR20070008625A (ko) * | 2004-04-05 | 2007-01-17 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
GB0411411D0 (en) * | 2004-05-21 | 2004-06-23 | Glaxosmithkline Biolog Sa | Vaccines |
WO2005117958A1 (en) | 2004-05-28 | 2005-12-15 | Glaxosmithkline Biologicals S.A. | Vaccine compositions comprising virosomes and a saponin adjuvant |
WO2006002422A2 (en) | 2004-06-24 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Compounds for immunopotentiation |
AU2005333126A1 (en) * | 2004-07-18 | 2006-12-21 | Csl Limited | Methods and compositions for inducing innate immune responses |
EP1781325A2 (en) * | 2004-07-18 | 2007-05-09 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
DE102004038535B4 (de) * | 2004-08-06 | 2012-10-04 | Universitätsklinikum Schleswig-Holstein | Zelluläre Einschleusung von Nukleinsäurewirkstoffen |
WO2006076678A2 (en) * | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
NZ555937A (en) | 2005-01-27 | 2009-05-31 | Childrens Hosp & Res Ct Oak | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
MX2007014390A (es) * | 2005-05-19 | 2008-02-12 | Glaxosmithkline Biolog Sa | Composicion de vacuna que comprende subunidad b de termo toxina e. coli y antigeno y adyuvante. |
US8703095B2 (en) * | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
AR054822A1 (es) * | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
FR2888117B1 (fr) * | 2005-07-07 | 2009-10-09 | Sanofi Pasteur Sa | Composition vaccinale comprenant une emulsion thermoreversible |
DK1909830T3 (da) * | 2005-08-02 | 2011-12-19 | Novartis Vaccines & Diagnostic | Formindskelse af interferens mellem olieholdige adjuvanser og antigener indeholdende overfladeaktivt middel |
US20090087456A1 (en) * | 2005-09-07 | 2009-04-02 | James Edward Eyles | Adjuvanted vaccine |
KR20080066712A (ko) * | 2005-09-30 | 2008-07-16 | 티티아이 엘뷰 가부시키가이샤 | 관능화된 미세바늘 경피 약물 전달 시스템, 장치 및 방법 |
US20070078376A1 (en) * | 2005-09-30 | 2007-04-05 | Smith Gregory A | Functionalized microneedles transdermal drug delivery systems, devices, and methods |
US20070083186A1 (en) * | 2005-09-30 | 2007-04-12 | Darrick Carter | Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles |
WO2007052163A2 (en) * | 2005-11-01 | 2007-05-10 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
EP2368572B1 (en) | 2005-11-04 | 2020-03-04 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
EP1951300B1 (en) * | 2005-11-04 | 2011-06-22 | Novartis Vaccines and Diagnostics S.r.l. | Changing th1/th2 balance in split influenza vaccines with adjuvants |
US20110180430A1 (en) * | 2005-11-04 | 2011-07-28 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines including cytokine-inducing agents |
GB0524408D0 (en) * | 2005-11-30 | 2006-01-11 | Glaxosmithkline Biolog Sa | Vaccines |
GB0524409D0 (en) * | 2005-11-30 | 2006-01-11 | Glaxosmithkline Biolog Sa | Vaccines |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
EP1973608A1 (en) | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
EP1973564B1 (en) | 2005-12-22 | 2016-11-09 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
WO2007079190A2 (en) * | 2005-12-29 | 2007-07-12 | Tti Ellebeau, Inc. | Device and method for enhancing immune response by electrical stimulation |
FR2896162B1 (fr) * | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
KR101541383B1 (ko) | 2006-03-30 | 2015-08-03 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
SG173336A1 (en) | 2006-03-31 | 2011-08-29 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
EP2390358A1 (en) | 2006-06-02 | 2011-11-30 | GlaxoSmithKline Biologicals S.A. | Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the GZMK gene |
WO2007144150A1 (en) | 2006-06-12 | 2007-12-21 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
US9364525B2 (en) | 2006-07-18 | 2016-06-14 | Glaxosmithkline Biologicals Sa | Vaccines for malaria |
WO2008012538A2 (en) | 2006-07-25 | 2008-01-31 | The Secretary Of State For Defence | Live vaccine strains of francisella |
US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
ES2657392T3 (es) | 2006-09-26 | 2018-03-05 | Infectious Disease Research Institute | Composición de vacuna que contiene un adyuvante sintético |
WO2008057529A2 (en) * | 2006-11-06 | 2008-05-15 | Coley Pharmaceutical Group, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp) |
CN101563090B (zh) * | 2006-11-20 | 2013-01-02 | 杜科姆公司 | 包含南美皂皮树皂苷的含脂质颗粒用于治疗癌症的用途 |
WO2008112125A1 (en) * | 2007-03-09 | 2008-09-18 | Merck & Co., Inc. | Papillomavirus vaccine compositions |
US8518903B2 (en) | 2007-04-19 | 2013-08-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of toll-like receptor-9 agonists |
KR20100010509A (ko) * | 2007-05-17 | 2010-02-01 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 면역자극 효과를 갖는 a 클래스 올리고뉴클레오타이드 |
US20100183662A1 (en) | 2007-06-26 | 2010-07-22 | Ralph Leon Biemans | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
WO2009027105A2 (en) | 2007-08-31 | 2009-03-05 | Neurimmune Therapeutics Ag | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders |
EP2034022A1 (en) * | 2007-09-10 | 2009-03-11 | Universite Libre De Bruxelles | Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus |
PL2198007T3 (pl) | 2007-09-14 | 2018-03-30 | Sanofi Pasteur Biologics, Llc | Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile |
CA2699853A1 (en) | 2007-09-17 | 2009-03-26 | Oncomethylome Sciences Sa | Improved detection of mage-a expression |
EP2197497B1 (en) | 2007-09-27 | 2016-06-01 | ImmunoVaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
EP2045263A1 (en) | 2007-10-02 | 2009-04-08 | Universite Libre De Bruxelles | Identification and molecular characterisation of salivary metalloproteases expressed in the tick salivary glands |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
EP2244695A1 (en) | 2007-12-07 | 2010-11-03 | Novartis AG | Compositions for inducing immune responses |
WO2009105641A2 (en) | 2008-02-20 | 2009-08-27 | New York University | Preventing and treating amyloid-beta deposition by stimulation of innate immunity |
ES2557282T3 (es) | 2008-03-10 | 2016-01-25 | Children's Hospital & Research Center At Oakland | Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso |
EP2296696B1 (en) | 2008-06-05 | 2014-08-27 | ImmunoVaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
JP5659332B2 (ja) | 2008-06-27 | 2015-01-28 | ゾエティス・エルエルシー | 新規なアジュバント組成物 |
AU2012258478B2 (en) * | 2008-06-27 | 2013-10-03 | Zoetis Services Llc | Novel adjuvant compositions |
WO2010036293A1 (en) * | 2008-09-24 | 2010-04-01 | The Johns Hokins University | Malaria vaccine |
WO2010041143A2 (en) * | 2008-10-08 | 2010-04-15 | Immune Solutions Limited | Oral vaccines for producing mucosal immunity |
CN102245198B (zh) | 2008-12-09 | 2016-08-17 | 辉瑞疫苗有限责任公司 | IgE CH3肽疫苗 |
GB0901411D0 (en) | 2009-01-29 | 2009-03-11 | Secr Defence | Treatment |
GB0901423D0 (en) | 2009-01-29 | 2009-03-11 | Secr Defence | Treatment |
KR101825697B1 (ko) | 2009-02-10 | 2018-02-05 | 노파르티스 아게 | 감소된 양의 스쿠알렌을 포함하는 인플루엔자 백신 |
SG2014014385A (en) * | 2009-02-17 | 2014-04-28 | Glaxosmithkline Biolog Sa | Inactivated dengue virus vaccine with aluminium-free adjuvant |
AU2014200047C1 (en) * | 2009-02-17 | 2017-01-19 | Glaxosmithkline Biologicals S.A. | Inactivated dengue virus vaccine with aluminium-free adjuvant |
KR20120002534A (ko) | 2009-03-17 | 2012-01-05 | 엠디엑스헬스 에스에이 | 유전자 발현의 향상된 검출 |
GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
PT2437753T (pt) | 2009-06-05 | 2016-11-23 | Infectious Disease Res Inst | Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos |
RU2518291C2 (ru) | 2009-07-30 | 2014-06-10 | Пфайзер Вэксинс ЭлЭлСи | Антигенные tau-пептиды и их применения |
GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
AU2010293059B2 (en) * | 2009-08-26 | 2017-03-16 | Selecta Biosciences, Inc. | Compositions that induce T cell help |
SG178447A1 (en) | 2009-09-03 | 2012-03-29 | Pfizer Vaccines Llc | Pcsk9 vaccine |
GB0917457D0 (en) | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
US9234037B2 (en) | 2009-10-27 | 2016-01-12 | Ucb Biopharma Sprl | Method to generate antibodies to ion channels |
GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
CN102781963B (zh) | 2009-10-27 | 2018-02-16 | Ucb医药有限公司 | 功能修饰性NAv1.7抗体 |
US20130034573A1 (en) | 2009-12-22 | 2013-02-07 | Celldex Therapeutics, Inc. | Vaccine compositions |
WO2012020326A1 (en) * | 2010-03-18 | 2012-02-16 | Novartis Ag | Adjuvanted vaccines for serogroup b meningococcus |
WO2011126863A1 (en) | 2010-03-30 | 2011-10-13 | Children's Hospital & Research Center Oakland | Factor h binding proteins (fhbp) with altered properties and methods of use thereof |
EA201500857A1 (ru) | 2010-05-26 | 2016-06-30 | Селекта Байосайенсиз, Инк. | Комбинированные вакцины с синтетическими наноносителями |
EP2942061A3 (en) | 2010-06-07 | 2016-01-13 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
WO2011154863A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Inc. | Her-2 peptides and vaccines |
US20130259948A1 (en) | 2010-09-21 | 2013-10-03 | National Institute Of Immunology | Spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles |
US9072760B2 (en) | 2010-09-24 | 2015-07-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders |
US10668092B2 (en) | 2010-09-24 | 2020-06-02 | The John Hopkins University | Compositions and methods for treatment of inflammatory disorders |
EP2637687B1 (en) | 2010-11-08 | 2021-01-06 | Infectious Disease Research Institute | Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis |
WO2012088425A2 (en) | 2010-12-22 | 2012-06-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease |
GB201022007D0 (en) | 2010-12-24 | 2011-02-02 | Imp Innovations Ltd | DNA-sensor |
CA2826920A1 (en) | 2011-02-15 | 2012-08-23 | Immune Design Corp. | Methods for enhancing immunogen specific immune responses by vectored vaccines |
WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
MX350795B (es) | 2011-04-08 | 2017-09-19 | Inmune Design Corp | Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares. |
PL3505531T3 (pl) | 2011-04-22 | 2024-03-11 | Wyeth Llc | Kompozycje związane ze zmutowaną toksyną Clostridium difficile i sposoby ich wytwarzania |
AU2012257771C1 (en) | 2011-05-17 | 2015-12-03 | Glaxosmithkline Biologicals S.A. | Vaccine against Streptococcus pneumoniae |
EA201490381A1 (ru) | 2011-07-29 | 2014-06-30 | Селекта Байосайенсиз, Инк. | Синтетические наноносители, которые стимулируют формирование гуморального иммунного ответа и иммунного ответа, опосредованного цитотоксическими т-лимфоцитами (ctl) |
GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
CN103998058B (zh) | 2011-10-06 | 2021-11-05 | 免疫疫苗技术有限公司 | 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用 |
MY184576A (en) | 2011-11-23 | 2021-04-06 | In3Bio Ltd | Recombinant proteins and their therapeutic uses |
LT2811981T (lt) | 2012-02-07 | 2019-06-10 | Infectious Disease Research Institute | Pagerintos adjuvanto kompozicijos, apimančios tlr4 agonistus, ir jų panaudojimo būdai |
EP2659906A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
SG10201603896RA (en) | 2012-05-04 | 2016-07-28 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
LT2850431T (lt) | 2012-05-16 | 2018-06-25 | Immune Design Corp. | Vakcinos, skirtos hsv-2 |
US9562066B2 (en) * | 2012-09-25 | 2017-02-07 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oral therapy of necrotizing enterocolitis |
BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
JP2016502995A (ja) * | 2012-12-17 | 2016-02-01 | ユーロシネ ヴァクシンズ アクチエボラーグ | 鼻腔内予防接種投薬レジメン |
DK2961388T3 (da) * | 2013-03-01 | 2019-07-08 | Astex Pharmaceuticals Inc | Kombinationer af lægemidler |
BR112015023402A2 (pt) | 2013-03-15 | 2017-08-22 | Bioven 3 Ltd | Proteínas sintéticas de automontagem |
EP4059450A1 (en) * | 2013-03-15 | 2022-09-21 | Corium, Inc. | Microstructure array for delivery of active agents |
WO2014160987A2 (en) | 2013-03-28 | 2014-10-02 | Infectious Disease Research Institute | Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis |
JP6426706B2 (ja) | 2013-04-18 | 2018-11-21 | イミューン デザイン コーポレイション | がん処置で使用するためのgla単剤療法 |
AU2014385320B2 (en) | 2013-05-15 | 2019-10-10 | The Governors Of The University Of Alberta | E1E2 HCV vaccines and methods of use |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
CA2924526A1 (en) * | 2013-09-19 | 2015-03-26 | Paul Joseph Dominowski | Water-in-oil emulsions comprising immunostimulatory oligonucleotides |
KR102411781B1 (ko) | 2013-12-31 | 2022-06-22 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | 단일 바이알 백신 제형 |
NZ755769A (en) | 2014-01-21 | 2023-06-30 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
EP3104877B1 (en) | 2014-02-11 | 2020-01-22 | The USA, as represented by The Secretary, Department of Health and Human Services | Pcsk9 vaccine and methods of using the same |
CA2955015A1 (en) | 2014-07-15 | 2016-01-21 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
JP6796057B2 (ja) | 2014-07-23 | 2020-12-02 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | H因子結合タンパク質変異体及びその使用方法 |
IL252915B2 (en) | 2015-01-15 | 2024-04-01 | Pfizer | Immunogenic preparations for use in pneumococcal vaccines |
AR103427A1 (es) | 2015-01-16 | 2017-05-10 | Zoetis Services Llc | Vacuna contra la fiebre aftosa |
CN104857511B (zh) * | 2015-02-13 | 2018-03-30 | 浙江大学 | 含人参皂甙的疫苗稀释剂 |
EP3078381A1 (en) * | 2015-04-10 | 2016-10-12 | Warszawski Uniwersytet Medyczny | Horse chestnut extract or escins for the treatment of alzheimer's disease |
AU2016271857B2 (en) | 2015-06-03 | 2020-05-28 | Affiris Ag | IL-23-P19 vaccines |
WO2017005851A1 (en) | 2015-07-07 | 2017-01-12 | Affiris Ag | Vaccines for the treatment and prevention of ige mediated diseases |
TWI756893B (zh) | 2015-07-21 | 2022-03-01 | 美商輝瑞股份有限公司 | 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途 |
JP6884145B2 (ja) | 2015-11-20 | 2021-06-09 | ファイザー・インク | 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物 |
JP6820935B2 (ja) | 2016-01-19 | 2021-01-27 | ファイザー・インク | がんワクチン |
CN105770887A (zh) * | 2016-03-04 | 2016-07-20 | 邓招红 | 一种用于hbv疫苗的佐剂及其制备方法 |
US11162945B2 (en) | 2016-04-11 | 2021-11-02 | Board Of Regents, The University Of Texas System | Methods and compositions for detecting single T cell receptor affinity and sequence |
JP7195147B2 (ja) | 2016-05-16 | 2022-12-23 | アクセス ツー アドバンスト ヘルス インスティチュート | Peg化リポソームおよび使用方法 |
DK3458475T3 (da) | 2016-05-16 | 2022-09-12 | Access To Advanced Health Inst | Formulering, der indeholder tlr-agonist, og anvendelsesfremgangsmåder |
IL298227B2 (en) | 2016-06-01 | 2024-09-01 | Access To Advanced Health Inst | Nanoalum particles containing a fixing factor |
CA3036218A1 (en) | 2016-09-16 | 2018-03-22 | Infectious Disease Research Institute | Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy |
WO2018134693A1 (en) | 2017-01-20 | 2018-07-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
SG11201909331UA (en) | 2017-04-18 | 2019-11-28 | Fujifilm Cellular Dynamics Inc | Antigen-specific immune effector cells |
JP2020524143A (ja) | 2017-06-15 | 2020-08-13 | インフェクシャス ディズィーズ リサーチ インスティチュート | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
MX2020000636A (es) | 2017-07-18 | 2020-08-20 | In3Bio Ltd | Proteinas sinteticas y usos terapeuticos de las mismas. |
EP3678695A1 (en) | 2017-09-08 | 2020-07-15 | Infectious Disease Research Institute | Liposomal formulations comprising saponin and methods of use |
US20200254081A1 (en) | 2017-09-28 | 2020-08-13 | Pfizer Inc. | Compositions and methods for eliciting an immune response against clostridium difficile |
US11633471B2 (en) | 2018-03-06 | 2023-04-25 | Unm Rainforest Innovations | Compositions and methods for reducing serum triglycerides |
US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
EP3856241A4 (en) * | 2018-09-27 | 2022-10-05 | Genocea Biosciences, Inc. | TREATMENT PROCESSES |
JP2022513076A (ja) | 2018-11-19 | 2022-02-07 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Carおよびtcr形質導入用のモジュール式ポリシストロニックベクター |
AU2019386140A1 (en) | 2018-11-28 | 2021-06-24 | Board Of Regents, The University Of Texas System | Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment |
BR112021010248A2 (pt) | 2018-11-29 | 2021-08-17 | Board Of Regents, The University Of Texas System | métodos para expansão ex vivo de células naturais killer e uso dos mesmos |
US20220016229A1 (en) | 2018-12-12 | 2022-01-20 | Pfizer Inc. | Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof |
GB201901608D0 (en) | 2019-02-06 | 2019-03-27 | Vib Vzw | Vaccine adjuvant conjugates |
JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
WO2020201985A1 (en) | 2019-04-01 | 2020-10-08 | Pfizer Inc. | Compositions and methods for eliciting an immune response against clostridium difficile |
US20220184199A1 (en) | 2019-04-10 | 2022-06-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
WO2020232407A1 (en) * | 2019-05-16 | 2020-11-19 | Trustees Of Tufts College | Peptide antibiotics and methods of use thereof |
JP2022532944A (ja) | 2019-05-25 | 2022-07-20 | アクセス ツー アドバンスト ヘルス インスティチュート | アジュバントワクチンエマルジョンを噴霧乾燥するための組成物および方法 |
EP3990010A1 (en) | 2019-06-25 | 2022-05-04 | In3Bio Ltd. | Stabilized chimeric synthetic proteins and therapeutic uses thereof |
CA3159573A1 (en) | 2019-11-01 | 2021-05-06 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
US20220396797A1 (en) | 2019-11-15 | 2022-12-15 | Infectious Disease Research Institute | Rig-i agonist and adjuvant formulation for tumor treatment |
CN112972672B (zh) * | 2019-12-13 | 2024-04-19 | 远大赛威信生命科学(南京)有限公司 | 药物组合物及其用途 |
CN111057738A (zh) * | 2020-01-02 | 2020-04-24 | 浙江大学 | C2c12细胞在疫苗佐剂机制研究中的用途和研究分析方法 |
CA3168337A1 (en) | 2020-02-17 | 2021-08-26 | Marie-Andree Forget | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
WO2021165847A1 (en) | 2020-02-21 | 2021-08-26 | Pfizer Inc. | Purification of saccharides |
IL295632A (en) | 2020-02-23 | 2022-10-01 | Pfizer | Escherichia coli preparations and their methods |
AU2021252164A1 (en) | 2020-04-09 | 2022-12-15 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
EP4168032A2 (en) | 2020-06-19 | 2023-04-26 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
EP4000603A4 (en) * | 2020-06-30 | 2023-08-09 | Eyegene, Inc. | SAPONIN-INDUCED HEMOLYSIS INHIBITION COMPOSITION CONTAINING A CATIONIC LIPOSOME |
US20230310569A1 (en) | 2020-09-04 | 2023-10-05 | Access To Advanced Health Institute | Genetically-adjuvanted rna vaccines |
CA3174411A1 (en) | 2020-09-04 | 2022-03-10 | Ryan M. Kramer | Co-lyophilized rna and nanostructured lipid carrier |
TW202227467A (zh) | 2020-10-27 | 2022-07-16 | 美商輝瑞大藥廠 | 大腸桿菌組合物及其方法 |
IL302413A (en) | 2020-11-04 | 2023-06-01 | Pfizer | Immunogenic preparations for use in pneumococcal vaccines |
CA3200968A1 (en) | 2020-11-10 | 2022-05-19 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
CA3201499A1 (en) | 2020-11-13 | 2022-05-19 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
US20220162288A1 (en) | 2020-11-25 | 2022-05-26 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
US20220202923A1 (en) | 2020-12-23 | 2022-06-30 | Pfizer Inc. | E. coli fimh mutants and uses thereof |
MX2023007648A (es) | 2020-12-23 | 2023-08-29 | Access To Advanced Health Inst | Adyuvantes de vacuna de solanesol y métodos para prepararlos. |
CA3211240A1 (en) | 2021-02-19 | 2022-08-25 | Sanofi Pasteur Inc. | Meningococcal b recombinant vaccine |
PE20240090A1 (es) | 2021-05-28 | 2024-01-16 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos |
EP4346893A2 (en) | 2021-05-28 | 2024-04-10 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
CA3228262A1 (en) | 2021-08-04 | 2023-02-09 | The Regents Of The University Of Colorado, A Body Corporate | Lat activating chimeric antigen receptor t cells and methods of use thereof |
CN113797329A (zh) * | 2021-10-19 | 2021-12-17 | 启锰生物科技(江苏)有限公司 | 一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法 |
EP4433080A1 (en) | 2021-11-18 | 2024-09-25 | Matrivax, Inc. | Immunogenic fusion protein compositions and methods of use thereof |
WO2023089556A1 (en) | 2021-11-22 | 2023-05-25 | Pfizer Inc. | Reducing risk of antigen mimicry in immunogenic medicaments |
CN116212012A (zh) * | 2021-12-02 | 2023-06-06 | 上海泽润生物科技有限公司 | 复合佐剂以及包含它的疫苗制剂 |
KR20240128715A (ko) | 2022-01-13 | 2024-08-26 | 화이자 인코포레이티드 | 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도 |
WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
WO2023211972A1 (en) | 2022-04-28 | 2023-11-02 | Medical University Of South Carolina | Chimeric antigen receptor modified regulatory t cells for treating cancer |
WO2023218322A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Process for producing of vaccine formulations with preservatives |
WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
US20240181028A1 (en) | 2022-11-22 | 2024-06-06 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2024116096A1 (en) | 2022-12-01 | 2024-06-06 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
US20240189410A1 (en) | 2022-12-13 | 2024-06-13 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
CN116159134A (zh) * | 2023-01-31 | 2023-05-26 | 四川大学 | 七叶皂苷和/或其盐化合物作为佐剂在疫苗中的应用 |
WO2024166008A1 (en) | 2023-02-10 | 2024-08-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2024201324A2 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2024214016A1 (en) | 2023-04-14 | 2024-10-17 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US4806350A (en) * | 1986-04-18 | 1989-02-21 | Norden Laboratories, Inc. | Vaccine formulation |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
UA40597C2 (uk) | 1992-06-25 | 2001-08-15 | Смітклайн Бічем Байолоджікалс С.А. | Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів |
ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
GB9503863D0 (en) | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
GB9620795D0 (en) | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6251405B1 (en) | 1995-06-07 | 2001-06-26 | Connaught Laboratories, Inc. | Immunological combination compositions and methods |
ES2241042T3 (es) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora. |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US6231859B1 (en) * | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
JP4153999B2 (ja) | 1996-12-20 | 2008-09-24 | アルザ・コーポレーション | 経皮作用剤流量を強化するための組成物と方法 |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
JP2001513776A (ja) * | 1997-02-28 | 2001-09-04 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | LPS関連障害の処置における非メチル化CpGジヌクレオチドを含む核酸の使用 |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
AU753688B2 (en) | 1997-03-10 | 2002-10-24 | Ottawa Civic Loeb Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6627198B2 (en) * | 1997-03-13 | 2003-09-30 | Corixa Corporation | Fusion proteins of Mycobacterium tuberculosis antigens and their uses |
US6589940B1 (en) * | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
AU753172B2 (en) | 1997-06-06 | 2002-10-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
EP0988053A1 (en) * | 1997-06-11 | 2000-03-29 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
CA2654522C (en) | 1997-08-29 | 2014-01-28 | Antigenics Inc. | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient |
GB9718901D0 (en) * | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
GB9727262D0 (en) * | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
SI1077722T1 (sl) * | 1998-05-22 | 2007-02-28 | Ottawa Health Research Inst | Metode in produkti za induciranje sluznicne imunosti |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
US7049302B1 (en) * | 1998-08-10 | 2006-05-23 | Antigenics Inc. | Compositions of CPG and saponin adjuvants and uses thereof |
KR100922031B1 (ko) * | 1999-04-19 | 2009-10-19 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
WO2001051083A2 (en) * | 2000-01-13 | 2001-07-19 | Antigenics Inc. | Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
CA2396871A1 (en) * | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
-
2000
- 2000-04-04 KR KR1020077027021A patent/KR100922031B1/ko not_active IP Right Cessation
- 2000-04-04 JP JP2000611936A patent/JP2002542203A/ja active Pending
- 2000-04-04 CZ CZ20013774A patent/CZ303515B6/cs not_active IP Right Cessation
- 2000-04-04 CN CNB008088365A patent/CN1227030C/zh not_active Expired - Lifetime
- 2000-04-04 DE DE60014076T patent/DE60014076T2/de not_active Expired - Lifetime
- 2000-04-04 EP EP00920647A patent/EP1187629B1/en not_active Revoked
- 2000-04-04 IL IL14598200A patent/IL145982A0/xx unknown
- 2000-04-04 PT PT00920647T patent/PT1187629E/pt unknown
- 2000-04-04 TR TR2001/03018T patent/TR200103018T2/xx unknown
- 2000-04-04 WO PCT/EP2000/002920 patent/WO2000062800A2/en active Application Filing
- 2000-04-04 BR BRPI0010612A patent/BRPI0010612B8/pt not_active IP Right Cessation
- 2000-04-04 DK DK00920647T patent/DK1187629T3/da active
- 2000-04-04 AU AU41149/00A patent/AU764969B2/en not_active Ceased
- 2000-04-04 CA CA2370697A patent/CA2370697C/en not_active Expired - Lifetime
- 2000-04-04 AT AT00920647T patent/ATE276758T1/de active
- 2000-04-04 ES ES00920647T patent/ES2228497T3/es not_active Expired - Lifetime
- 2000-04-04 PL PL351893A patent/PL203951B1/pl unknown
- 2000-04-04 EP EP10177594A patent/EP2322210A1/en not_active Withdrawn
- 2000-04-04 HU HU0200815A patent/HU229255B1/hu unknown
- 2000-04-18 TW TW089107209A patent/TWI232753B/zh not_active IP Right Cessation
- 2000-10-18 US US09/690,921 patent/US6544518B1/en not_active Expired - Lifetime
-
2001
- 2001-10-18 NO NO20015073A patent/NO331688B1/no not_active IP Right Cessation
-
2002
- 2002-08-22 HK HK02106189.6A patent/HK1044484B/zh not_active IP Right Cessation
-
2003
- 2003-03-03 US US10/379,164 patent/US7399472B2/en not_active Expired - Fee Related
-
2007
- 2007-04-04 JP JP2007098596A patent/JP4897547B2/ja not_active Expired - Lifetime
- 2007-11-09 JP JP2007291459A patent/JP4805242B2/ja not_active Expired - Lifetime
- 2007-12-20 US US11/934,206 patent/US20080095788A1/en not_active Abandoned
-
2008
- 2008-07-11 US US12/171,770 patent/US20080311156A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002542203A5 (ja) | ||
CA2370697A1 (en) | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide | |
ES2295229T3 (es) | Vacunas contra canceres. | |
AU2002244337A1 (en) | Vaccines | |
García et al. | An overview of adjuvant formulations and delivery systems | |
JP2008285487A (ja) | ワクチン | |
JP2007536326A (ja) | Mage−3およびny−eso−1に基づく癌免疫療法用多価ワクチン | |
MXPA03003406A (es) | Composicion adyuvante que comprende un oligonucleotido inmunoestimulador y un tocol. | |
JP2007508272A (ja) | インターロイキン18およびサポニンアジュバント系を含むワクチン組成物 | |
US20040013649A1 (en) | Cancer vaccines and methods of using the same | |
EP1503793A2 (en) | Cancer vaccines and methods of using the same | |
PL203894B1 (pl) | Kompozycja szczepionki i sposób jej wytwarzania, oraz zastosowanie |